Active Ingredient(s):Canakinumab FDA Approved: * June 17, 2009 Pharm Company: *NOVARTIS PHARMS Category:Anti-Inflammatory
Canakinumab (INN), sold under the brand name Ilaris, is a medication for the treatment of systemic juvenile idiopathic arthritis (SJIA) and active Still's disease, including adult-onset Still's disease (AOSD). It is a human monoclonal antibody targeted at interleukin-1 beta. It has no cross-reactivity with other members of the interleukin-1 family, including interleukin-1 alpha.
Common side effects include infections (colds and upper re...
* May have multiple approval dates, manufacturers, or labelers. 3 Discussions
Ilaris 150 mg/ml Subcutaneous Injection, Powder, Lyophilized, for Solution